AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2020

Apr 15, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2020-04-13

Reporting Person: Bowden Christopher (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-13	Common stock	M	5280	—	Acquired	10598	Direct
2020-04-14	Common stock	F	2368	$40.64	Disposed	8230	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-04-13	Performance share units	$	M	5280	Disposed		Common stock (5280.0)	Direct

Footnotes

F1: Each performance share unit represents a contingent right to receive one share of the issuer's common stock.

F2: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified commercial milestone was determined to have been met on April 13, 2020, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested.